Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Filed with HKEX · Stock code 6998 · · 11 pages · English
Summary by 6ix AI
The report confirms the total authorized share capital and provides details on movements in issued and treasury shares. It also includes a public float sufficiency confirmation, indicating compliance with the applicable public float requirements. The filing outlines specific changes in issued shares and treasury shares, including share repurchases during the month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Edding Genor Group Holdings Limited on 6ix
Earlier from Edding Genor
- Next Day Disclosure Return
- 2026 Interim Report
- EDG Announced Phase Ib/II Clinical Trial of GB268 Obtained IND Approval by NMPA
- Edding Genor Group Holdings: EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial
- Releases Its Interim Results for 2023
Later from Edding Genor
- Voluntary announcement - IND approval from the NMPA for Phase II clinical trial of GB268 in colorectal cancer
- Voluntary announcement - first-in-human phase i study data of GB268 presented at the esmo congress 2026
Follow Edding Genor into a list and get an email when it puts out news.
Follow Edding Genor